IPO Proposal of Yambaling Hydropower Limited And Sopan Pharmaceuticals Limited Approved by SEBON

The Securities Board of Nepal (SEBON) has granted the Initial Public Offering (IPO) proposal of Yambaling Hydropower Limited. The issue is approved on Falgun 17, 2082.

According to the approved proposal, the company will issue a total of 28,00,000 units of shares to the general public at a par value of Rs. 100 per unit. The shares will be available for subscription by both local investors and the general public.

Muktinath Capital Limited has been appointed the issue manager for the public offering.

CARE Ratings Nepal Limited (CRNL) has reaffirmed the issuer rating of CARE-NP BB- (Is) for Yambaling Hydropower Limited (YHL). In Nepal, issuers with this rating are considered to carry a moderate risk of default in meeting their financial obligations on time.

Yambaling Hydropower Limited (YHL), established in 2007 and converted to a public company in 2021, operates the 7.27 MW run-of-river Yambaling Khola Hydropower Project in Sindhupalchowk, Nepal, which began commercial operations on February 20, 2024, under a BOOT (Build, Own, Operate, Transfer) arrangement.

The Securities Board of Nepal (SEBON) has granted the Initial Public Offering (IPO) proposal of Sopan Pharmaceuticals Limited. The issue is approved on Falgun 17, 2082.

According to the approved proposal, the company will issue a total of 42,90,000 units of shares to the general public at a par value of Rs. 100 per unit.

NMB Capital Limited has been appointed the issue manager for the public offering.

CARE Ratings Nepal Limited (CRNL) has upgraded the issuer rating of Sopan Pharmaceuticals Limited (SPL) from CARE-NP B- (Is) to CARE-NP B (Is), indicating a high risk of default. The long-term bank facility rating was also revised to CARE-NP B, while the short-term bank facility rating of CARE-NP A4 was reaffirmed.

Sopan Pharmaceuticals Limited (SPL), a public company incorporated in 2009 and promoted by both institutional and individual stakeholders, manufactures generic and cephalosporin drugs at its Lalitpur facility in Nepal, holding licenses for 139 types of drugs for production and 70 types for marketing.